featured
Tislelizumab vs Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal SCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
J. Clin. Oncol 2022 Apr 20;[EPub Ahead of Print], L Shen, K Kato, SB Kim, JA Ajani, K Zhao, Z He, X Yu, Y Shu, Q Luo, J Wang, Z Chen, Z Niu, L Zhang, T Yi, JM Sun, J Chen, G Yu, CY Lin, H Hara, Q Bi, T Satoh, R Pazo-Cid, HT Arkenau, C Borg, F Lordick, L Li, N Ding, A Tao, J Shi, E Van CutsemFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.